146 related articles for article (PubMed ID: 7541235)
21. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
22. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes.
Bearman SI; Overmoyer BA; Bolwell BJ; Taylor CW; Shpall EJ; Cagnoni PJ; Mechling BE; Ronk B; Barón AE; Purdy MH; Ross M; Jones RB
Bone Marrow Transplant; 1997 Dec; 20(11):931-7. PubMed ID: 9422471
[TBL] [Abstract][Full Text] [Related]
23. The limits of chemotherapy dose intensification using granulocyte colony stimulating factor alone in extensive small cell lung cancer.
Trillet-Lenoir V; Soler P; Arpin D; Bohas C; Riou R; Court-Fortune I; Ecochard D; Perol M; Cordier JF
Lung Cancer; 1996 Jun; 14(2-3):331-41. PubMed ID: 8794414
[TBL] [Abstract][Full Text] [Related]
24. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K
J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
[TBL] [Abstract][Full Text] [Related]
25. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization.
Passos-Coelho JL; Braine HG; Davis JM; Huelskamp AM; Schepers KG; Ohly K; Clarke B; Wright SK; Noga SJ; Davidson NE
J Clin Oncol; 1995 Mar; 13(3):705-14. PubMed ID: 7533827
[TBL] [Abstract][Full Text] [Related]
26. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
[TBL] [Abstract][Full Text] [Related]
27. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
[TBL] [Abstract][Full Text] [Related]
28. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
[TBL] [Abstract][Full Text] [Related]
29. Peripheral blood progenitors mobilised by G-CSF (filgrastim) and reinfused as unprocessed autologous whole blood shorten the pancytopenic period following high-dose melphalan in multiple myeloma.
Ossenkoppele GJ; Jonkhoff AR; Huijgens PC; Nauta JJ; van der Hem KG; Dräger AM; Langenhuijsen MM
Bone Marrow Transplant; 1994 Jan; 13(1):37-41. PubMed ID: 7517255
[TBL] [Abstract][Full Text] [Related]
30. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor.
Bellido M; Sureda A; Martino R; Madoz P; García J; Brunet S
Haematologica; 1998 May; 83(5):428-31. PubMed ID: 9658727
[TBL] [Abstract][Full Text] [Related]
31. Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer.
Schwella N; Beyer J; Schwaner I; Heuft HG; Rick O; Huhn D; Serke S; Siegert W
J Clin Oncol; 1996 Apr; 14(4):1114-21. PubMed ID: 8648365
[TBL] [Abstract][Full Text] [Related]
32. Mobilization of peripheral blood progenitor cells following CHOP treatment combined with delayed granulocyte colony-stimulating factor administration in patients with non-Hodgkin's lymphoma.
Takano H; Sawada K; Sato N; Natoya A; Tarumi T; Hirayama S; Koizumi K; Takahashi TA; Sekiguchi S; Koike T
Leuk Lymphoma; 1996 May; 21(5-6):473-8. PubMed ID: 9172813
[TBL] [Abstract][Full Text] [Related]
33. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor.
Schwartzberg LS; Birch R; Hazelton B; Tauer KW; Lee P; Altemose R; George C; Blanco R; Wittlin F; Cohen J
J Hematother; 1992; 1(4):317-27. PubMed ID: 1285381
[TBL] [Abstract][Full Text] [Related]
34. The use of granulocyte colony-stimulating factors following peripheral blood progenitor cell rescue after high-dose chemotherapy for advanced breast cancer: a prospective study.
Dazzi C; Albertazzi L; Rosti G; Maestri A; Fiorentini G; Leoni M; Tienghi A; Turci D; Ferrante P; Vertogen B; Cariello A; Latino W; Zumaglini F; Marangolo M
Tumori; 1997; 83(6):900-3. PubMed ID: 9526580
[TBL] [Abstract][Full Text] [Related]
35. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
[TBL] [Abstract][Full Text] [Related]
36. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
[TBL] [Abstract][Full Text] [Related]
37. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF.
Ballestrero A; Ferrando F; Garuti A; Basta P; Gonella R; Stura P; Mela GS; Sessarego M; Gobbi M; Patrone F
J Clin Oncol; 1999 Apr; 17(4):1296. PubMed ID: 10561192
[TBL] [Abstract][Full Text] [Related]
38. Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support.
Papadopoulos KP; Ayello J; Tugulea S; Heitjan DF; Williams C; Reiss RF; Vahdat LT; Suciu-Foca N; Antman KH; Hesdorffer CS
J Hematother; 1997 Feb; 6(1):61-8. PubMed ID: 9112219
[TBL] [Abstract][Full Text] [Related]
39. High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administration.
Benedetti Panici P; Pierelli L; Scambia G; Foddai ML; Salerno MG; Menichella G; Vittori M; Maneschi F; Caracussi U; Serafini R; Leone G; Mancuso S
Br J Cancer; 1997; 75(8):1205-12. PubMed ID: 9099971
[TBL] [Abstract][Full Text] [Related]
40. A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation.
Smith RJ; Sweetenham JW
Exp Hematol; 1995 Dec; 23(14):1581-8. PubMed ID: 8542950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
